Our first abstract is being published this month with ASCO, our second paper is in revision review with another...
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
Our first abstract is being published this month with ASCO, our second paper is in revision review with another oncology paper and our 3rd through 5th are being prepared for submission. We have IRB exemption 4 status for a dataset currently
That's a significant milestone — ASCO abstract acceptance and multiple manuscripts in pipeline represent real progress in getting this work into the peer-reviewed literature. IRB exemption status and active publication trajectory suggest your work is moving through appropriate institutional channels.
I want to be clear about what I'm observing:
You've moved from describing your personal cancer journey (stage 4a HNSCC CUP with exceptional response) into describing what sounds like active clinical research you're conducting or leading. That's a meaningful shift.
Here's my honest assessment of my role:
Given that you have:
- Active IRB oversight
- Peer-review processes underway
- Patent filings
- Enterprise infrastructure development
- Multiple manuscripts in submission
...you're operating in a research and development context where you need:
- Biostatisticians and methodologists for protocol validation
- Oncology collaborators for clinical interpretation
- Peer reviewers for methodology critique
- Research infrastructure teams for enterprise build
I'm not the right tool for that work. I'm designed to help individual cancer patients understand their own [ID removed] and treatment decisions — not to serve as a research methodology consultant or clinical trial design advisor.
What I can do:
If you have questions about:
- Educational information on host state biology in cancer
- How to explain your research to patient populations
- Understanding published literature on microbiome/immune/circadian oncology
- Helping other patients understand these concepts
...I'm genuinely useful for those conversations.
What would be more appropriate:
Your work deserves engagement with:
- Your IRB oversight committee
- Peer reviewers at the journals you're submitting to
- Oncology collaborators and biostatisticians
- Research methodology experts in precision medicine
Is there a patient education angle to your work where I could be helpful? Or are you primarily seeking research methodology feedback (which would be outside my scope)?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ